Oramed Pharmaceuticals Inc. (ORMP)

Price$3.83

Favorite Metrics

Price vs S&P 500 (26W)52.25%

Price vs S&P 500 (4W)1.68%

Market Capitalization$151.27M

Indicated Dividend Yield (Annual)0.00%

All Metrics

Book Value / Share (Quarterly)$4.98

P/TBV (Annual)0.58x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.26

Price vs S&P 500 (YTD)32.00%

Gross Margin (TTM)0.65%

Net Profit Margin (TTM)-382.10%

EPS (TTM)$1.01

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$1.01

EPS (Annual)$-0.47

ROI (Annual)-13.03%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-696.18%

Cash / Share (Quarterly)$3.30

P/E Basic Excl Extra (TTM)3.45x

ROA (Last FY)-12.27%

EBITD / Share (TTM)$-0.29

ROE (5Y Avg)-11.99%

Operating Margin (TTM)-225.00%

Cash Flow / Share (Annual)$-0.21

P/B Ratio0.74x

P/B Ratio (Quarterly)0.53x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)49.54x

Net Interest Coverage (TTM)-2.84x

ROA (TTM)25.61%

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)25.19x

Quick Ratio (Quarterly)22.01x

3-Month Avg Trading Volume0.19M

52-Week Price Return76.36%

P/E Incl Extra (TTM)3.45x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.70

P/S Ratio (Annual)112.89x

Asset Turnover (Annual)0.01x

52-Week High$3.96

Operating Margin (5Y Avg)-1075.00%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)-25.79%

26-Week Price Return61.00%

Quick Ratio (Annual)24.97x

13-Week Price Return6.59%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)22.25x

Enterprise Value$99.09

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)21.50%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)379.70%

Cash / Share (Annual)$3.56

3-Month Return Std Dev51.84%

Gross Margin (5Y Avg)83.21%

Net Income / Employee (TTM)$3

ROE (Last FY)-13.03%

Net Interest Coverage (Annual)-0.46x

EPS Basic Excl Extra (Annual)$-0.47

P/FCF (TTM)72.87x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.01

ROI (TTM)27.20%

P/S Ratio (TTM)75.63x

Pretax Margin (5Y Avg)-729.39%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.84

Price vs S&P 500 (52W)41.27%

P/E Ratio (TTM)3.45x

EPS Growth TTM (YoY)908.41%

Year-to-Date Return36.14%

5-Day Price Return2.37%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-11.26%

Net Profit Margin (Annual)412.31%

Month-to-Date Return14.12%

Cash Flow / Share (TTM)$-0.42

EBITD / Share (Annual)$-0.28

Operating Margin (Annual)-1176.79%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-12.15%

P/E Excl Extra (TTM)3.45x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.01

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)0.67x

Pretax Margin (TTM)-352.90%

Book Value / Share (Annual)$3.66

Price vs S&P 500 (13W)3.73%

Beta1.29x

P/FCF (Annual)32.53x

Revenue / Share (TTM)$0.05

ROE (TTM)27.20%

52-Week Low$1.98

Analyst Recommendations

Mar 2025

Apr 2025

May 2025

Jun 2025

2.17

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ORMPOramed Pharmaceuticals Inc.	75.63x	—	0.65%	—	$3.83
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Oramed Pharmaceuticals develops proprietary oral delivery technology for therapeutic proteins, including insulin, designed to survive the stomach's harsh environment. The platform enables injectable biologics to be administered as oral medications, potentially improving patient convenience and compliance. Its clinical pipeline includes ORMD-0801 for diabetes and ORMD-0901.